Skip to content

If Chronic Gallbladder Diseases Increase the Incidence of PEC

If Chronic Gallbladder Diseases Increase the Occurence of Post Endoscopic Retrograde Choledochopancreatography Choledocholithiasis(a Prospective Multi-center Cohort Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04242394
Enrollment
1019
Registered
2020-01-27
Start date
2020-02-14
Completion date
2024-11-16
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis

Keywords

ERCP, Acute purulent cholecystitis, Bile duct stone, Post-ERCP-Choledocholithiasis PEC

Brief summary

This is a prospective, multi-centre trial conducts at 4 ERCP centers in China designed to determine if chronic gallbladder diseases increase the incidence of Post-Endoscopic Retrograde Choledochopancreatography-Choledocholithiasis (PEC)

Detailed description

Endoscopic Retrograde Choledochopancreatography(ERCP) has the advantages of less injury and faster recovery for common bile duct stone patients. However, according to our retrospective study, ERCP will has a mostly 10% possibility to get an acute purulent cholecystitis which often requires emergency intervention, when patients combined with chronic gallbladder diseases, such as chronic cholecystitis, asymptomatic gallstones, and gallbladder wall thickness, the incidence of PEC will increase accordingly. The aim of this study is to observe if chronic gallbladder disease will increase the occurence of PEC and develop a high-risk PEC model.

Interventions

PROCEDUREERCP

Routine ERCP procedures with gallbladder in situ patient

Sponsors

Hepatopancreatobiliary Surgery Institute of Gansu Province
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* ERCP patients with gallbladder in situ

Exclusion criteria

* Acute cholecystitis before surgery * Gallbladder has been removed * Gastrointestinal reconstruction * Unwillingness or inability to consent for the study * Unstable vital signs Coagulation dysfunction (INR\>1.5) * Low peripheral blood platelet count (\<50×10 \^9 / L) or using anti-coagulation drugs * Preoperative coexistent diseases: acute pancreatitis, GI tract hemorrhage, severe liver disease (such as decompensated liver cirrhosis, liver failure and so on), septic shock Biliary- duodenal fistula confirmed during ERCP * Pregnant women or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Number of Acute PEC(post-ERCP-cholecystitis )1monthWhen the PEC occurs, with right upper abdominal pain, White Blood Cell increasing, gallbladder wall ≥4mm or crudely, temperature might be more than 38 degree centigrade

Secondary

MeasureTime frameDescription
Number of Pancreatitis1monthTypical abdominal pain, with the level of serum amylase increasing at least 3 times of the normal range within 24 hours after ERCP.
Number of Cholangitis1 monthTemperature should be more than 38 #, right upper abdominal pain, chills or WBC≥10
Number of Perforation1 monthTypical abdominal pain,abdominal muscle tension, tenderness, evidence of free gas in abdominal cavity

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026